Oxonica, one of the United Kingdom's leading nanotechnology companies (see Nature 446, 963; 2007), has lost its latest legal fight over intellectual-property rights to a fuel additive.
"We are disappointed that we lost the action," Matthews told Nature. Matthews resigned on 24 June, and will leave the company at the end of September. On 17 July chief financial officer Richard Clarke also resigned, to leave at the same time as Matthews. It has not been decided who will run the company after that. "It's not a comfortable position to be in," says Matthews. "But the reality is it's a demanding time for early stage businesses. Obviously losing a legal battle at this point in time is not particularly helpful to us." On 24 July, shareholders approved delisting the company from AIM on 4 August.
Matthews says the company's future is assured, but it will involve "significantly simplifying the business". Oxonica is likely to partner its businesses with other companies, as it did with its Nanoplex diagnostics technology in 2006 by partnering with BD, a medical technology company in Franklin Lakes, New Jersey, in a deal that brought in $7 million. "It will be a royalties business not an operations business," says Matthews, adding that he is leaving because he isn't needed in a company without operations.
